KeyBanc Maintains AbCellera Biologics(ABCL.US) With Buy Rating
Benchmark Co. Downgrades AbCellera Biologics(ABCL.US) to Hold Rating
Strong Liquidity and Strategic Alliances Underpin Buy Rating for AbCellera Biologics
Understanding the Buy Rating: A Synopsis of AbCellera Biologics' Investment Potential
TD Cowen Maintains AbCellera Biologics(ABCL.US) With Buy Rating
TD Cowen Remains a Buy on AbCellera Biologics (ABCL)
KeyBanc Adjusts Price Target on AbCellera Biologics to $5 From $7, Maintains Overweight Rating
AbCellera Biologics Analyst Ratings
Keybanc Maintains Overweight on AbCellera Biologics, Lowers Price Target to $5
KeyBanc Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
Keybanc: Maintaining the ABCellera Biologics (ABCL.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $8.00 to $7.00.
AbCellera Biologics Analyst Ratings
Keybanc Maintains Overweight on AbCellera Biologics, Lowers Price Target to $7
Analysts Are Bullish on These Healthcare Stocks: ICU Medical (ICUI), AbCellera Biologics (ABCL)
Piper Sandler Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target Is $9
AbCellera Biologics Analyst Ratings
AbCellera Biologics Analyst Ratings
Stifel Nicolaus Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)